Although IDH inhibitors have shown clinical efficacy in various cancers, their high cost (approximately USD 33,693 per 28-day cycle for ivosidenib) relative to traditional chemotherapy highlights the importance of identifying predictive biomarkers to optimize patient selection and treatment outcomes [40]. Here, IDH2 is linked to cancer.